U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H20F3N5O2
Molecular Weight 455.4324
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Redafamdastat

SMILES

FC(F)(F)C1=CN=C(OC2=CC(C=C3CCN(CC3)C(=O)NC4=NN=CC=C4)=CC=C2)C=C1

InChI

InChIKey=BATCTBJIJJEPHM-UHFFFAOYSA-N
InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32)

HIDE SMILES / InChI

Molecular Formula C23H20F3N5O2
Molecular Weight 455.4324
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

PF-04457845 is a fatty acid amide hydrolase 1 inhibitor developed by Pfizer for the treatment of inflammatory and noninflammatory pain disorders. The drug was tested in phase II in patients with osteoarthritis of the knee, but found to have the same effect as placebo. It was also assessed in phase II clinical trial for its effect on marijuana withdrawal and Tourette syndrome.

CNS Activity

Curator's Comment: PF-04457845 crossed blood-brain barrier in rats.

Originator

Curator's Comment: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.2 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Curative
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
129 ng/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04457845 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
442 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04457845 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1420 ng × h/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04457845 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6048 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04457845 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
21.9 h
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04457845 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
22.8 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04457845 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
2011 Feb 10
Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.
2014 Feb
Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.
2014 Feb 14
Patents

Sample Use Guides

Take 4 mg tablet once daily
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 03:07:40 UTC 2023
Edited
by admin
on Sat Dec 16 03:07:40 UTC 2023
Record UNII
H4C81M8YYW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Redafamdastat
Common Name English
PF-4457845
Code English
redafamdastat [INN]
Common Name English
N-3-Pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-1-piperidinecarboxamide
Systematic Name English
PF-04457845
Code English
1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-
Systematic Name English
Code System Code Type Description
CAS
1020315-31-4
Created by admin on Sat Dec 16 03:07:40 UTC 2023 , Edited by admin on Sat Dec 16 03:07:40 UTC 2023
PRIMARY
PUBCHEM
24771824
Created by admin on Sat Dec 16 03:07:40 UTC 2023 , Edited by admin on Sat Dec 16 03:07:40 UTC 2023
PRIMARY
WIKIPEDIA
PF-04457845
Created by admin on Sat Dec 16 03:07:40 UTC 2023 , Edited by admin on Sat Dec 16 03:07:40 UTC 2023
PRIMARY
EPA CompTox
DTXSID00144539
Created by admin on Sat Dec 16 03:07:40 UTC 2023 , Edited by admin on Sat Dec 16 03:07:40 UTC 2023
PRIMARY
SMS_ID
300000032092
Created by admin on Sat Dec 16 03:07:40 UTC 2023 , Edited by admin on Sat Dec 16 03:07:40 UTC 2023
PRIMARY
INN
12589
Created by admin on Sat Dec 16 03:07:40 UTC 2023 , Edited by admin on Sat Dec 16 03:07:40 UTC 2023
PRIMARY
DRUG BANK
DB12012
Created by admin on Sat Dec 16 03:07:40 UTC 2023 , Edited by admin on Sat Dec 16 03:07:40 UTC 2023
PRIMARY
FDA UNII
H4C81M8YYW
Created by admin on Sat Dec 16 03:07:40 UTC 2023 , Edited by admin on Sat Dec 16 03:07:40 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IRREVERSIBLE INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY